Abstract: A pharmaceutical composition is disclosed, which contains a short-acting .beta.-blocking compound of the formula ##STR1## wherein R.sub.1 may be an alkyl, cycloalkyl, alkenyl, alkynyl, alkyl carboxymethyl, aryl carboxymethyl, aryl or aralkyl, A may be an alkylene or alkenylene, X may be independently amino, hydrogen, halogen, hydroxy, alkoxy, aryloxy, aralkyl, cyano, amido or trifluoromethyl, n is an integer from 1 to about 4, R may be an alkyl, propargyl, dimethylpropargyl or hydroxyalkyl; or a pharmaceutically acceptable salt thereof in a hydroalcoholic solution further containing a physiologically acceptable buffering agent, ethanol and a physiologically acceptable liquid polyhydric compound. A method for treatment or prophylaxis of cardiac disorders using the composition of the present invention is also disclosed.

Abstract: This invention relates to insecticidal compositions containing N'-substituted-N,N'-diacylhydrazines, methods of using such compositions and certain novel insecticidal N'-substituted-N,N'-diacylhydrazines.

Abstract: Solid dihydropyridines, e.g. nifedipine and nimodipine preparations having a maximum standard deviation of the active compound content of 3% contain 1 part by weight of nifedipine, 2 to 6 parts by weight of PVP with a mean molecular weight of 15,000 to 50,000, 3.5 to 15 parts by weight of cellulose, 0.25 to 4 parts by weight of starch and 0.5 to 4 parts by weight of cross-linked insoluble PVPP, and, if appropriate, one or more further pharmaceutical auxiliaries and excipients. These preparations show a good release of dihydropyridine with good content uniformity.

Abstract: Novel 19-nor-steroids of the formula ##STR1## wherein R.sub.1 is an organic group of 1 to 18 carbon atoms optionally containing at leat one heteroatom with the atom immediately adjacent the 11-carbon atom being carbon, R.sub.2 is a hydrocarbon of 1 to 8 carbon atoms, X is the remainder of a pentagonal or hexagonal ring optionally substituted and optionally containing one unsaturated bond, the A and B rings are selected from the group consisting of ##STR2## R' and R" are individually selected from the group consisting of hydrogen, --CN and alkyl of 1 to 4 carbon atoms, R.sub.x is selected from the group consisting of hydrogen and OR.sub.e, R.sub.e is selected from the group consisting of hydrogen, optionally substituted alkyl of 1 to 6 carbon atoms and acyl, R.sub.a may be in the E or Z positions as indicated by the wavy line and is selected from the group consisting of ##STR3## and acyloxy, R.sub.a ' and R.sub.

Abstract: A hair-growing agent which exhibits a strong hair-growing effect. The hair-growing agent according to the present invention contains as an effective ingredient an aliphatic carboxylic acid having an odd number of carbon atoms or a derivative thereof.

Abstract: A composition for in vivo inhibition of aromatase in a mammal, which comprises an in vivo inhibitory amount of a compound having the following general formula: ##STR1## wherein R.sub.1 is hydrogen or C.sub.1-4 acyl, in combination with as pharmaceutically acceptable carrier or diluent thereof.

Abstract: Novel Vitamin D.sub.3 derivatives of the following formula ##STR1## wherein R represents a hydrogen atom or a lower alkyl group. These compounds have an activity of inducing differentiation of tumor cells, and are useful for anti-tumor agents. On the other hand, the compounds have almost no vitamin D activity.

Abstract: Invented are sulfonic acid substituted analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-.alpha.-reductase, including using these compounds to reduce or maintain prostate size. Also invented are intermediates used in preparing these compounds.

Abstract: This invention relates to the use of clomiphene in preventing osteoporosis in humans and treating human patients experiencing osteoporosis.

Abstract: A 21-alkoxysteroid compound represented by the formula ##STR1## wherein R.sup.1 is an alkyl group having 1 to 4 carbon atoms or a methylthiomethyl group, R.sup.2 is an alkanoyl group having 2 to 7 carbon atoms, and a wavy line indicates the .alpha.- or .beta.-configuration has anti-inflammatory activity.

Abstract: 16.alpha.-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperaziny l]pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate causes hemolysis when injected. However, when formulated with a citric acid/sodium citrate both the hemolysis and hypotension side effects are prevented.

Abstract: This invention is directed to 4-substituted 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepared by the hydride reduction of an appropriate steroidal imine or enamine.

Abstract: A pharmaceutical composition suitable for oral administration comprises micronized progesterone in an oil vehicle which is high in glycerides of polyunsaturated fatty acids. Micronized progesterone particles suspended in such an oil vehicle are absorbed more readily into the bloodstream and achieve high progesterone blood serum levels. The pharmaceutical composition according to the invention can be readily formulated into capsules and administered for the treatment of premenstrual syndrome.

Abstract: Contraceptive methods and delivery systems involving few undesirable side effects during administration are based on novel triphasic estrogen/progestogen combinations, wherein the amount of estrogen is increased stepwise over the three phases.

Abstract: Compounds of the general Formula (I) ##STR1## in which R is a hydrogen atom or a bromine atom, and R.sub.1 is a hydrogen atom, an SO.sub.2 OM group wherein M is a hydrogen or sodium atom, various sulphatide or phosphatide groups or a glucuronide group are disclosed for use in the prophylaxis and therapy of retroviral infections, especially infection by Human Immunodeficiency Virus. These compounds may be used concomitantly or in combination with various immunomodulators and/or antiviral agents.

Abstract: Disclosed is synthesized dihydrotestosterone heptanoate, its method of synthesis, and its method of use as an androgenic hormone of male gynecomastia, as a hormonal probe, as well as other applications.

Abstract: The present invention is directed to a method for the treatment of hyperaldosteronism and related disorders which comprises administering to an appropriate patient an appropriate 17.beta.-cyclopropylaminoandrostene.

Abstract: A 11.beta.-aryl-19-norprogesterone steroid of the formula: ##STR1## wherein (i) R.sup.1 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, OH, OC(O)CH.sub.3, or OC(O)R.sup.5, wherein R.sup.5 is C.sub.2-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl or aryl, R.sub.2 is H, R.sup.3 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl, R.sup.4 is H, CH.sub.3, F or Cl, R.sup.6 is H, (CH.sub.3).sub.2 N, CH.sub.3 O, CH.sub.3 CO, CH.sub.3 S, CH.sub.3 SO, CH.sub.3 SO.sub.2, and X is O or NOCH.sub.3 ; or(ii) R.sup.1 and R.sup.2 taken together are a carbon-carbon bond and R.sup.3, R.sup.4, R.sup.6 and X are as defined above; or(iii) R.sup.1 and R.sup.3 taken together are --CH.sub.2 -- or --N.dbd.N--CH.sub.2 --, R.sup.2 is H and R.sup.4, R.sup.6 and X are as defined above; or(iv) R.sup.2 and R.sup.3 taken together are .dbd.CH.sub.2 and R.sup.1, R.sup.4, R.sup.6 and X are as defined above.

Abstract: A composition is provided which includes a balanced combination of an edrophonium component and an atropine component. A preferred embodiment has 0.5 mg of edrophonium chloride and 8 micrograms of atropine sulfate, with respect to patient weight. The inventive composition is useful to antagonize nondepolarizing blockade during medical treatment when muscle relaxation is no longer necessary, provides extremely rapid onset of action and results in minimal heart rate changes.

Abstract: The present invention discloses a process for the production of androsta-4,9(11)-diene-3,17-dione type compounds from 9.alpha.-hydroxyandrostenedione type compounds by non-aromatic oxygenated strong acid dehydration.